GlassScriptPhysician profile
Michael Mardiney
NPI 1609827724
$3,031.78
in general payments reported to CMS, 2019-2025
28 companies · $80.30 in 2025
The $80.30 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $397 · 2021: $841 · 2022: $1,425 · 2023: $28.36 · 2024: $24.84 · 2025: $80.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $75.00 · Food and Beverage: $58.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $75.00 |
| Food and Beverage | $58.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $710.18 | 2019-2022 | |
| Glaxosmithkline, LLC. | $389.29 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $288.69 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $265.41 | 2019-2022 | |
| Genentech USA, INC. | $184.94 | 2019-2022 | |
| Genzyme Corporation | $173.46 | 2020-2022 | |
| Optinose US, INC. | $160.84 | 2019-2022 | |
| Abbvie INC. | $123.28 | 2022 | |
| Sanofi-Aventis U.S. LLC | $114.97 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.21 | 2020-2023 | Cuvitru |
| Ionis Pharmaceuticals, INC. | $75.00 | 2025 | |
| Pfizer INC. | $58.11 | 2021-2022 | |
| Csl Behring | $43.07 | 2020-2021 | |
| Biocryst US Sales Co., LLC | $40.52 | 2021 | |
| Amgen INC. | $39.23 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $38.34 | 2020-2022 | |
| Biocryst Pharmaceuticals, INC. | $32.80 | 2020 | |
| Horizon Therapeutics Plc | $27.01 | 2020 | |
| Leo Pharma INC. | $24.84 | 2024 | Adbry |
| Phadia US INC. | $24.17 | 2019 | |
| Uswm, LLC | $23.00 | 2021 | |
| Alk-Abello, INC | $22.93 | 2020 | |
| Mylan Specialty L.P. | $18.11 | 2020 | |
| Mylan Pharmaceuticals INC. | $17.86 | 2020 | |
| Kaleo, INC. | $14.51 | 2019 | |
| Merck Sharp & Dohme LLC | $13.59 | 2019 | |
| Aimmune Therapeutics, INC. | $13.12 | 2022 | |
| Organon LLC | $5.30 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mardiney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.